• Delmar Pharmaceuticals Inc., of Vancouver, British Columbia, opened its third clinical trial site at the Brain Tumor Center at University of California, San Francisco. Delmar is conducting a Phase I/II dose-escalation study designed to assess the safety and activity of VAL-083 as a potential treatment for brain cancer patients suffering from glioblastoma multiforme (GBM) who have failed standard therapies and have no viable treatment options.